Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

nadofaragene firadenovec-vncg

View Patient Information
A replication-deficient recombinant adenovirus encoding human interferon alpha-2b with potential antineoplastic activity. Upon intravesical administration, nadofaragene firadenovec-vncg infects nearby tumor cells and expresses INF alpha-2b intracellularly which activates the transcription and translation of genes whose products mediate antiviral, antiproliferative, antitumor, and immune-modulating effects.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:nadofaragene firadenovec
nadofaragene firadenovec/Syn3
recombinant adenovirus-interferon SCH 721015
recombinant adenovirus-interferon with Syn3
recombinant adenovirus-interferon/Syn3
US brand name:Adstiladrin
Abbreviation:rAd-IFN
rAd-IFN-2b
rAd-IFN/Syn3
Code name:SCH 721015
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search